Categories Earnings, Health Care
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG): Q3 2019 Earnings Snapshot
— AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) reported a net loss of $23.62 million or $0.70 per share for the third quarter of 2019, vs. $0.66 per share loss expected
— Revenues dropped to $84.13 million from $122.24 million last year, vs. $88.27 million expected
— Lowered full-year 2019 revenue guidance to $320-$330 million from the earlier outlook of $325-$355 million
— Expects full-year operating loss of $278-$268 million, up from $276 million loss estimated earlier
— Expects adjusted EBITDA loss in the range of $75 million to $65 million for 2019, which is down from the previous forecast of $85-$75 million
Most Popular
BIIB Earnings: Biogen Q1 2024 adj. earnings rise despite lower revenues
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Wednesday reported an increase in adjusted profit for the first quarter of 2024, despite a decline in revenues. Total revenue declined 7% year-over-year to
Hasbro (HAS) Q1 2024 Earnings: Key financials and quarterly highlights
Hasbro, Inc. (NASDAQ: HAS) reported first quarter 2024 earnings results today. Revenues decreased 24% year-over-year to $757.3 million. Net earnings attributable to Hasbro, Inc. were $58.2 million, or $0.42 per
BA Earnings: Highlights of Boeing’s Q1 2024 financial results
The Boeing Company (NYSE: BA) on Wednesday announced financial results for the first quarter of 2024, reporting a narrower net loss, on an adjusted basis. Revenues dropped 8%. Core loss,